Related Experiment Video
Updated: Aug 15, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Determining efficacy of cancer chemopreventive agents using a cell-free system concomitant with DNA adduction
1Graduate Center for Toxicology, Room 354, Health Sciences Research Building, University of Kentucky Medical Center, Lexington, KY 40536-0305, USA.
Abstract:
The large (>2000) and expanding number of natural and synthetic agents with potential cancer chemopreventive properties renders it economically and physically impossible to test each of these agents for their efficacy in the widely accepted 2-year animal bioassay and clinical trials. Therefore, there is a growing need for relevant short-term screening tests to study these compounds such that only the most efficacious ones undergo extensive long-term studies. We have previously reported in a pilot study that the use of a microsome-mediated test system concomitant with DNA adduction is a pertinent and relevant model for rapidly studying the efficacy and mechanisms of cancer chemopreventive agents. We have extended this study to investigate 26 additional agents for their potential chemopreventive abilities by studying their effects on microsome-mediated benzo[a]pyrene (BP)-DNA adduction. These agents had differential effects on the two major adducts of BP-DNA, i.e., BP-7,8-diol-9,10-epoxide (BPDE)-deoxyguanosine (dG) and 9-OH-BP-dG-derived adducts. These agents were therefore categorized into five classes. Three test agents (ellagic acid, genistein and oltipraz) were strong inhibitors of both adducts. These agents diminished BP-DNA adduction by 65-95% and were categorized as Class I agents. Six other agents (benzyl isocyanate, R(+)-1-phenylethyl isocyanate, linoleic acid ethyl ester, (+)-biotin, indole-3-carboxylic acid and beta-carotene) moderately inhibited both BP-DNA adducts (25-64%); these compounds were identified as Class II agents. Six additional test agents inhibited only one adduct selectively and nine others were ineffective; these agents were categorized as Class III and Class IV, respectively. Interestingly, seven test agents enhanced BPDE-dG or 9-OH-BP-dG or both adducts and were categorized as Class V agents. Four of these Class V agents concomitantly inhibited BPDE-dG while enhancing 9-OH-BP-dG. This emphasizes the importance of studying individual DNA adducts in contrast to total DNA binding. In conclusion, Class I and Class II agents may be good candidates for further chemoprevention studies.
Insights
Identifying effective cancer chemopreventive agents requires short-term screening. This study classified 26 agents based on their impact on benzo[a]pyrene (BP)-DNA adducts, identifying promising candidates for further research.
Area of Science:
- Chemoprevention research
- Molecular toxicology
- Biochemical screening
Background:
- The vast number of potential cancer chemopreventive agents necessitates efficient screening methods.
- Traditional long-term animal bioassays and clinical trials are economically and practically infeasible for initial testing.
- A pilot study demonstrated the utility of a microsome-mediated test system with DNA adduction for rapid efficacy assessment.
Purpose of the Study:
- To extend previous findings by evaluating 26 additional agents for cancer chemopreventive potential.
- To investigate the effects of these agents on microsome-mediated benzo[a]pyrene (BP)-DNA adduction.
- To categorize agents based on their differential effects on specific BP-DNA adducts.
Main Methods:
- Utilized a microsome-mediated test system to assess the impact of 26 agents on benzo[a]pyrene (BP)-DNA adduction.
- Analyzed the differential effects of agents on two major BP-DNA adducts: BP-7,8-diol-9,10-epoxide (BPDE)-deoxyguanosine (dG) and 9-OH-BP-dG.
- Categorized agents into five classes based on their inhibitory or enhancing effects on these specific adducts.
Main Results:
- Three agents (ellagic acid, genistein, oltipraz) strongly inhibited both BP-DNA adducts (Class I, 65-95% reduction).
- Six agents moderately inhibited both adducts (Class II, 25-64% reduction).
- Other agents showed selective inhibition, were ineffective, or enhanced adduct formation (Class III-V).
Conclusions:
- Class I and Class II agents, demonstrating significant inhibition of BP-DNA adducts, are promising candidates for further cancer chemoprevention studies.
- The study highlights the importance of analyzing individual DNA adducts rather than total DNA binding.
- The microsome-mediated DNA adduction assay serves as a valuable short-term screening tool for chemopreventive agents.
More Related Videos
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
11:58A Simple, Rapid, and Quantitative Assay to Measure Repair of DNA-protein Crosslinks on Plasmids Transfected into Mammalian Cells
Published on: March 5, 2018